Tag: Rexin-G News
Epeius Biotechnologies’ REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation from the U.S. FDA
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today that the U.S. FDA has granted Phase 3 status for Company's lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek-out and destroy metastatic cancer.
FDA Fast Track Designation for the Treatment of Pancreatic Cancer Given to Rexin-G®
SAN MARINO, Calif. /California Newswire/ -- Epeius Biotechnologies announced this week that its lead product, Rexin-G, has been granted Fast Track designation by the...
Rexin-G® Nano Particles Target Metastatic Cancers
SAN MARINO, Calif. /California Newswire/ -- Epeius Biotechnologies' Rexin-G is the world's smallest hero. Imagine if you will, a tiny particle that can travel...
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma
SAN MARINO, Calif. /California Newswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed...
